Transgene SA · EURONEXT:TNG

Transgene SA — Investor Presentation (September 2007)

31 slides from Transgene SA's investor presentation, September 2007

  1. Slide 1: Developing immunotherapeutics to fight cancer and infectious diseases

    Developing immunotherapeutics to fight cancer and infectious diseases transgene Philippe ARCHINARD, C.E.O. Philippe PONCET, C.F.O.

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s objectives for progress in its clinical trials and product candidate development as well as. Statements that are not historical facts are based on the Company's current expecta

  3. Slide 3: History

    History 1998 Initial Public Offering on Euronext and Nasdaq (€94m raised) Focus on cancer 2001 Follow-on: €63m raised Focus on therapeutic vaccines in cancer and infectious diseases 2005 Follow-on: €49m raised (incl. €14.3m in 2006) Roche worldwide exclusive licensing agreement for MVA-HPV-IL2 (TG 4

  4. Slide 4: Transgene Strategy: Leading Immunotherapy

    Transgene Strategy: Leading Immunotherapy Developing therapeutic vaccines and products to treat cancer and infectious diseases Strategy to partner with pharma companies for later stage development, i.e. Roche to develop the HPV franchise Transgene to develop and commercialise therapeutic vaccine pro

  5. Slide 5: Transgene Overview

    Transgene Overview Financial data: Market capitalization = € 371 million on September 11, 2007 Cash (July 2007) = approx. € 125 million Roche payments: € 23 million in June 2007 Capital increase in June 2007: € 100.1 million Estimated 2007 operating burn rate = € 25 million Public Mérieux Alliance G

  6. Slide 6: Transgene's share since January 2006

    Transgene’s share since January 2006… Price (€) Volume (shares) 11/04/07: 25 Partnership 600 000 agreement with 6/03/07: 2006 Roche annual results and 01/06/07: 2007 outlook Transgene receives first milestone 10/08/07 : payment of € 10M First half 2007 25/04/06: Positive 13/12/06: Agreement from Roc

  7. Slide 7: Sites

    Sites Headcount: 185 people Strasbourg (headquarters) Research Process development Clinical development Illkirch Biomanufacturing Kensington Clinical development U.S. Lyon Infectious diseases research 7 transgene

  8. Slide 8: Manufacturing: a strategic asset

    Manufacturing: a strategic asset 2500 m² plant near Strasbourg cGMP MVA & Adenovirus suites Clinical batches and first years of commercialisation 8 transgene

  9. Slide 9: Transgene's Pipeline

    Transgene’s Pipeline Clinical results for 3 products within 1 year Drug Candidate Indication Preclinical Phase I Phase II Phase III Next Partner or milestones Funding TG 4001 / R3484 Prevention of Initiation Ph. III Roche (MVA –HPV-IL2) Cervical Cancer H1 08 TG 4010 Non-Small Cell Phase IIb - (MVA-

  10. Slide 10: TG 4001/R3484: HPV-mediated Diseases

    TG 4001/ R3484: HPV-mediated Diseases 10 transgene

  11. Slide 11: Roche Partnership: A Significant Achievement for Transgene

    Roche Partnership: A Significant Achievement for Transgene Execution of our strategic plan announced in 2006. Validation of the MVA technology by a recognized pharmaceutical leader. Recognition of the R&D skills and therapeutic vaccination approach of Transgene. Derisking of Transgene’s product port

  12. Slide 12: Partnership with Roche on TG4001 / R3484 (MVA-HPV-IL2)

    Partnership with Roche on TG4001 / R3484(MVA-HPV-IL2) § Upfront: €13m Exclusive § Early milestone: €10m (june07) worldwide rights Roche will fund § Further clinical and sales for MVA-based all development milestones: €195m on various HPV therapeutic costs vaccines indications § Royalties: double dig

  13. Slide 13: Human Papilloma Virus (HPV) Infection

    Human Papilloma Virus (HPV) Infection The most prevalent sexually-transmitted infection 80% to 85% of women will be infected at least once in their lifetime, usually without symptoms. Highest infection rates are found in women under 25 years of age. Spontaneous clearance of the infection takes place

  14. Slide 14: HPV-mediated diseases: Infection to Cancer of the Cervix

    HPV-mediated diseases: Infection to Cancer of the Cervix HPV Infection Silent Infection GlaxoSmithKline - Cervarix Merck - Gardasil TG 4001 CIN 2/3 Average age = 35 years Prevention Invasive cancer Age 5 10 15 20 25 30 35 40 45 (years) 14 transgene

  15. Slide 15: Prevalency of different HPV Genotypes in EU and USA for CIN 2/3

    Prevalency of different HPV Genotypes in EU and USA for CIN 2/3 CIN2/3 100 Others HPV16-like 50 average= 80.9% HPV16 average= 0 50.8% 0 38 00 87 02 =5 =1 =4 ,3 ,2 N =4 =1 N N N N Clifford, 2003 Meta-analysis Padilla, 2003 Becker,1994 Schiffman, 1993 Roda Husman, 1994 52% EU, 19% Latin America Albuqu

  16. Slide 16: CIN2/3 Existing Therapy: Cone Biopsy

    CIN2/3 Existing Therapy: Cone Biopsy Surgical procedure under local or general anesthetic in hospital. Short term efficacy high but significant relapse rate (37% relapse after 2 years for HPV16 CIN 2/3 lesions). Associated with complications: Bleeding in 3.5 - 5% of cases (International Agency for R

  17. Slide 17: TG 4001/R3484: HPV Therapeutic Vaccine

    TG 4001/R3484: HPV Therapeutic Vaccine Product: Antigen-specific therapeutic vaccine (recombinant MVA vector expressing E6 and E7 antigens of HPV 16): MVA-HPV-IL2 Target: Prevention of cervical cancer by treating precancerous cervical lesions (CIN 2/3) caused by Human Papilloma Virus 16 (HPV 16) and

  18. Slide 18: TG 4001: HPV Therapeutic Vaccine

    TG 4001: HPV Therapeutic Vaccine TG4001 is effective to treat CIN2/3 precancerous lesions in Phase II 10 surgeries avoided on 21 patients (no more CIN2/3 lesions) Clinical data No HPV16 mRNA detected in the 10 women without CIN2/3 Sustainability of the results at 12 months ð Proof of concept of ther

  19. Slide 19: TG 4010: Non-Small Cell Lung Cancer

    TG 4010: Non-Small Cell Lung Cancer 19 transgene

  20. Slide 20: TG 4010: Non-Small Cell Lung Cancer

    TG 4010: Non-Small Cell Lung Cancer Product: Antigen-specific therapeutic vaccine / MVA-MUC1-IL2 Target: NSCLC: MUC1 is overexpressed in 60% of NSCLC patients First line treatment in combination with chemotherapy NSCLC Market potential: Worldwide incidence = 1.1 million per year Estimated mortality

  21. Slide 21: Positive TG 4010 Phase IIa Results

    Positive TG 4010 Phase IIa Results Clear clinical benefit from the combination therapy as compared to the standard cisplatin/vinorelbine chemotherapy 35 evaluable patients # patients Response rate (%) Partial responses 13/35 37% Stable disease 12/35 34% Clinical benefit 25/35 71% 1-year survival 53%

  22. Slide 22: TG 4010 clinical results

    TG 4010 clinical results Ongoing Phase IIb trial Primary objective : to assess the efficacy of TG 4010 combined with chemotherapy in comparison with chemotherapy alone 140 patients (67 evaluable/arm) to be recruited • Completion of recruitment: May 2007 First interim results around year end, final r

  23. Slide 23: TG 1042: Cutaneous B-Cell Lymphoma

    TG 1042: Cutaneous B-Cell Lymphoma 23 transgene

  24. Slide 24: TG 1042: Cutaneous Lymphoma

    TG 1042: Cutaneous Lymphoma Product: Non-specific therapeutic vaccine (immune enhancement): Ad-IFNγ. Target: Relapsing cutaneous lymphoma (a skin malignancy), either T-cell or B-cell. Other cancer indications under evaluation. Potential market: Cutaneous B-cell Lymphoma (CBCL). Orphan indication. Pr

  25. Slide 25: TG 4040: Chronic Hepatitis C

    TG 4040: Chronic Hepatitis C 25 transgene

  26. Slide 26: TG 4040 Therapeutic Vaccine for Chronic Hepatitis C

    TG 4040 Therapeutic Vaccine for Chronic Hepatitis C Product: Antigen-specific therapeutic vaccine: MVA-HCV. Target: Chronic hepatitis C infection. Market potential: 170-200 million people infected worldwide; 12 million people infected in the US; EU and Japan. In France, 500,000 people infected; 50%

  27. Slide 27: TG 4040: Chronic Hepatitis C

    TG 4040: Chronic Hepatitis C Initiation of Phase I in France in Q1 2007 Recruitment of 15 treatment-naïve patients by year-end Safety data: by year-end 2007 Immune response and viral load impact by Q3 2008 30% funded by government grant through Lyon-biopôle competitiveness cluster. Initiation of Pha

  28. Slide 28: Financial Results

    Financial Results IAS/IFRS; in € million (except for share data) H1 2007 2006 Revenues 24.7 5.5 Operating expenses (16.6) (28.0) R&D (13.1) (24.2) G&A (2.5) (3.8) Other gains & losses (1.0) - Profit or (Loss) from operations 8.1 (22.5) Interest income 0.4 0.5 Income tax - - Net profit (loss) 8.5 (22

  29. Slide 29: Strong Newsflow

    Strong Newsflow HPV (TG 4001) partnership – deal with Roche signed in April 2007 Recruitment completed for NSCLC (TG4010) in May 2007 - first interim results by year end First interim results for Cutaneous B-Cell Lymphoma (TG 1042) around year end First interim results for Hepatitis C (TG 4040) arou

  30. Slide 30: Strategic Objectives Going Forward

    Strategic Objectives Going Forward Three product candidates should be in Phase III or equivalent in 2008 (TG 4001, TG 4010, TG 1042). Conclude out-licensing deal for TG 4010 by end of 2008. Move a new product in the clinic from our own preclinical pipeline within one year. Establish a leadership pos

  31. Slide 31: Contacts Transgene

    11, rue de Molsheim 67082 Strasbourg Cedex France Contacts Transgene Tél. : + 33 (0) 3 88 27 91 21 Philippe Archinard, CEO Fax. : + 33 (0) 3 88 27 91 11 Philippe Poncet, CFO www.transgene.fr +33 (0) 3 88 27 91 00 31

Transgene — Investor Presentation (September 2007) on 6ix